WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H597120
CAS#: 8058-79-5
Description: Paraprost consists of 1-glutamic acid, alanine & glycine; used in prostate hypertrophy drug therapy.
Hodoodo Cat#: H597120
Name: Paraprost
CAS#: 8058-79-5
Chemical Formula: C10H21N3O8
Exact Mass: 0.00
Molecular Weight: 311.290
Elemental Analysis: C, 38.58; H, 6.80; N, 13.50; O, 41.12
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Paraprost;
IUPAC/Chemical Name: L-alanine compound with L-glutamic acid and glycine (1:1:1)
InChi Key: RBPVKPJDVPPRMI-AVXONLMPSA-N
InChi Code: InChI=1S/C5H9NO4.C3H7NO2.C2H5NO2/c6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;3-1-2(4)5/h3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1,3H2,(H,4,5)/t3-;2-;/m00./s1
SMILES Code: N[C@@H](CCC(O)=O)C(O)=O.N[C@@H](C)C(O)=O.NCC(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 311.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Wilt TJ, Macdonald R, Ishani A, Rutks I, Stark G. WITHDRAWN: Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2011 May 11;(5):CD001042. doi: 10.1002/14651858.CD001042.pub2. Review. PubMed PMID: 21563128.
2: Okada H. [BPH pharmacotherapy (miscellaneous)]. Nihon Rinsho. 2002 Dec;60 Suppl 11:367-72. Review. Japanese. PubMed PMID: 12599602.
3: Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001042. Review. Update in: Cochrane Database Syst Rev. 2011;(5):CD001042. PubMed PMID: 10796739.
4: MacDonald R, Ishani A, Rutks I, Wilt TJ. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int. 2000 May;85(7):836-41. Review. PubMed PMID: 10792162.
5: Mahoney JE. Plant extracts in the medical management of benign prostatic hyperplasia: fact or fiction? Can J Urol. 1995 May;2(2):125-9. PubMed PMID: 12803719.
6: Kumamoto Y, Tsukamoto T, Yachiku S, Kaneko S, Koyanagi T, Togashi M, Maru A, Tsuchida S, Nishizawa O, Orikasa S, et al. [A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy]. Hinyokika Kiyo. 1990 Oct;36(10):1213-32. Japanese. PubMed PMID: 1702262.
7: Maekawa M, Kishimoto T, Yasumoto R, Wada S, Harada T, Ohara T, Okajima E, Hirao Y, Ohzono S, Shimada K, et al. [Clinical evaluation of Cernilton on benign prostatic hypertrophy--a multiple center double-blind study with Paraprost]. Hinyokika Kiyo. 1990 Apr;36(4):495-516. Japanese. PubMed PMID: 1696065.
8: Yamaguchi O, Shiraiwa Y, Kobayashi M, Yokota T, Ohinata M, Aoki H, Tsuzuki T, Ohori M. Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study. Urol Int. 1990;45 Suppl 1:40-6. PubMed PMID: 1690481.
9: Aito K, Watsubo E. [The conservative treatment of prostatic hypertrophy with Paraprost]. Hinyokika Kiyo. 1972 Jan;18(1):41-4. Japanese. PubMed PMID: 4112552.